Developing Breast (Cancer) Organoids

ConditionBreast Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18+

SponsorMaastricht Radiation Oncology

About this trial

Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening.

This now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes.

Goal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are:

1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour? 2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions? 3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients? 4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female,

>18 years,

Family Anamneses

Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+).

Disqualifiers

None

Trial population

All breast cancer patients that meet the criteria mentioned above.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not an extra intervention, tissue taken in routine practice will be used.
Other intervention
No extra intervention: using tumour tissue taken during surgery in standard of care.

Treatment groups

60 Participants

are divided into 1 treatment group

Group A: All patients1 intervention

Trial outcomes

Primary outcomes

Living biobank

The development of a patient derived breast cancer living biobank using 3D organoid technology reflecting the most prominent clinical subtypes.

Time frame

12 months

Secondary outcomes

Organoids.

Cultivate breast cancer organoids that can be used to predict the treatment response to existing and novel combination treatments.

Time frame

12 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Maastricht Radiation Oncology

Lead sponsor

Maastricht University Medical Center

Collaborator

Maastricht University